October 9, 2025 – Talk Bio

Evommune Files for IPO to Fund Phase 2 Trials of Autoimmune Drug Candidates

1 day ago talkbio0Tagged autoimmune drugs, Chronic inflammatory disorder, EVO301, EVO756, Evommune, Funding, IPO, New York Stock Exchange, Phase 2 Trials, Series C financing

Evommune; IPO; Phase 2 trials; autoimmune drugs; EVO756; EVO301; chronic inflammatory diseases; biotech funding; New York Stock Exchange; Series C financing

Eli Lilly Commits Over $1 Billion to Expand India Manufacturing Footprint

1 day ago talkbio0Tagged contract manufacturing, eli lilly, Hyderabad, India, Investments, Manufacturing

Eli Lilly; India; manufacturing; investment; contract manufacturing; pharmaceuticals; Hyderabad

UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback

1 day ago talkbio0Tagged Consultation, drugmakers, Industry, Nance-Horan syndrome, payment, pharmaceutical rebates, Pricing, Response process, spending, statutory scheme, UK

UK medicine pricing; NHS spending; statutory scheme; drugmakers; payment percentage; pharmaceutical rebates; industry response; consultation 2025

Eli Lilly to Invest Over $1 Billion to Expand Manufacturing Footprint in India

1 day ago talkbio0Tagged Alzheimer 's, Autoimmune, contract manufacturing, Diabetes, eli lilly, expansion, Hyderabad, India, Malignant Neoplasms, Manufacturing, Obesity

Eli Lilly; India; manufacturing expansion; contract manufacturing; Hyderabad; pharmaceuticals; obesity; diabetes; Alzheimer’s; cancer; autoimmune

US Government Backs In Vivo Cell Therapy Startup with Major Funding

1 day ago talkbio0Tagged Cell Therapy, federal funding, Government, in vivo, startup, U.S.

federal funding; in vivo cell therapy; startup; immunoVec; US government

AI is Transforming Drug Safety—But Governance Sets Essential Guardrails

1 day ago talkbio0Tagged Adverse reaction to drug, AI guardrails, Artificial Intelligence, Bias (Epidemiology), Data Integrity, drug safety, Jeavons syndrome, patient safety, Pharmacovigilance, regulatory governance, United States Food and Drug Administration

artificial intelligence; drug safety; pharmacovigilance; adverse drug events; regulatory governance; FDA; EMEA; AI guardrails; data integrity; bias; patient safety

Ferring Pharmaceuticals to Cut 500 Jobs in Global Restructuring Effort

1 day ago talkbio0Tagged Ferring Pharmaceuticals, Global Restructuring, layoffs

Ferring Pharmaceuticals; Layoffs; Global Restructuring

Zenas BioPharma Inks $2 Billion+ Licensing Deal With InnoCare for Autoimmune Drug Candidates

2 days ago talkbio0Tagged Autoimmune Diseases, BTK inhibitor, Clinical Trials, Inhibitor, InnoCare, Interleukin-17, Multiple Sclerosis, orelabrtuinib, Pharma, TYK2 gene, Zenas BioPharma

Zenas BioPharma; InnoCare Pharma; autoimmune diseases; multiple sclerosis; BTK inhibitor; orelabrtuinib; licensing deal; clinical trials; IL-17 inhibitor; TYK2 inhibitor

The 5 Most Powerful Women in Biopharma: 2025 News & Key Figures

2 days ago talkbio0Tagged Belén, Biopharma, CEO, Garijo, Leadership, Reshma Kewalramani, Sarah Boyce, Woman, Women, Yvonne Greenstreet

powerful women; biopharma; female CEO; Reshma Kewalramani; Yvonne Greenstreet; Sarah Boyce; Emma Walmsley; Belén Garijo; leadership

Sanofi Challenges Novartis’ Dominance with Clinically Meaningful Pancreatic Tumor Data from AlphaMedix Phase II Trial

2 days ago talkbio0Tagged AlphaMedix, gastroenteropancreatic neuroendocrine tumors, GEP-NETs, Novartis, Orano, Overall Survival, Phase 2 Clinical Trials, Progression-Free Survival, radioligand therapy, Radiopharma, safety profile, sanofi

Sanofi; Novartis; radiopharma; AlphaMedix; Orano Med; gastroenteropancreatic neuroendocrine tumors; GEP-NETs; radioligand therapy; Phase II clinical trial; progression-free survival; overall survival; safety profile